Covid Seen as Tipping Point to Lower Drug Prices, Patent Sharing
April 22, 2020
If patient advocates push too hard to force the equivalent of open sourcing in medical research, it could discourage drugmakers from investing in new vaccines or treatments, ITIF's Stephen Ezell tells Bloomberg Law.
